Business
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the
About this update from Editas Medicine, Inc.
[{"type":"text","content":"On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on track to provide a clinical update by year-end Strengthened Executive Team with Appointments of Erick Lucera as Chief Financial Officer and Linda C. Burkly, Ph.D., as Chief Scientific Officer CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the second quarter 2023 and business updates. “We continued making significant progress against our strategic plan in the second quarter, specifically the advancement of our EDIT-301 program towards a BLA filing. The promising data we shared in June signal that EDIT-301 has the potential to be a clinically differentiated, one-time, durable medicine that can provide life changing clinical benefits to patients with sickle cell disease and beta thalassemia long term, specifically driving early and robust correction of anemia and sustained increases in fetal hemoglobin. The Editas team is excited and continues driving execution towards our goals,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “I’m also excited to welcome our new Chief Financial Officer, Erick Lucera, and our new Chief Scientific Officer, Linda Burkly, to the Editas leadership team, where they will utilize their respective experiences to build our in vivo pipeline, advance us towards becoming a commercial-stage organization, and transform the lives of people living with serious diseases.” Recent Achievements and Outlook Ex Vivo Hemoglobinopathies EDIT-301 for Sickle Cell Disease (SCD) Editas Medicine remains on track to dose 20 total SCD patients in the RUBY trial by year-end.The Company remains on track to provide an additional RUBY clinical update by year-end.In June, Editas Medicine presented positive initial clinical safety and efficacy data from the RUBY trial in an oral presentation at the European Hematology Association (EHA) Hybrid Congress in Frankfurt, Germany, and in a Company-sponsored webinar. EDIT-301 for Transfusion-dependent Beta Thalassemia (TDT) Editas Medicine has commenced parallel dosing in the EDITHAL trial for TDT.The Company remains on track to provide...